NCT04130516
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04130516
Title Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Linnaeus Therapeutics, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Cedars-Sinai Medical Center Los Angeles California 90048 United States Details
Yale Cancer Center New Haven Connecticut 06519 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87106 United States Details
Columbia University Herbert Irving Comprehensive Cancer Center New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
University of Pennsylvania Philadelphia Pennsylvania 19106 United States Details
Thomas Jefferson University, Sidney Kimmel Cancer Center Philadelphia Pennsylvania 19107 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
The START Center for Cancer Care San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field